๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Parkville
Clinical trial register · Australia

Clinical Trials in Parkville, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 3331 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:46 UTC
3331
Studies in scope
all four open statuses
1807
Recruiting now
open to new participants
758
Lead sponsors
across recruiting studies
Top sites
Melbourne 1087 Adelaide 564 Sydney 508 Westmead 416 Clayton 409
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Murdoch Childrens Research Institute16 Children's Oncology Group15 Hoffmann-La Roche15 BioMarin Pharmaceutical11 Novartis Pharmaceuticals10
Site location
Melbourne1087 Adelaide564 Sydney508 Westmead416 Clayton409
All 397 locations
Target enrolment
to

Trials with a site in Parkville

317 of 3331 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Not yet open
Speed of Lung Inflation During Ventilation of Extremely Preterm Infants
NCT07101419Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant
Murdoch Childrens Research Institute
Not applicable
68
Heidelberg, Parkville, Saint Albans
2027-02
Recruiting
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
NCT06840496Rett Syndrome
Biomed Industries, Inc.
Phase 3
210
Camperdown, South Brisbane, Heidelberg West, Parkville
2026-09-30
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
Sydney, Westmead, South Brisbane, Adelaide, East Melbourne, Parkville
2026-09-11
Recruiting
Describing the Effect of Familiar Song on Arousal and Awareness for Children With Disorders of Consciousness (DoC)
NCT07209657Disorder of Consciousness, Acquired Brain Injury
Murdoch Childrens Research Institute
Not applicable
10
Parkville
2026-09
Recruiting
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
NCT07630714Systemic Lupus Erythematosus
AstraZeneca
Phase 2
24
Parkville, Westmead
2026-08-31
Recruiting
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
NCT07298421Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
100
Parkville, Nedlands
2026-08-18
Recruiting
Feasibility Study of the iVEAcare Neuromodulation System for the Treatment of Drug-Resistant Epilepsy
NCT07640191Drug Resistant Epilepsy
iVEAcare
Not applicable
30
Herston, South Brisbane, Clayton, Fitzroy, Heidelberg, Melbourne, Parkville
2026-07-29
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
DrugElecoglipron
AstraZeneca
Phase 3
600
Campbelltown, East Toowoomba, Heidelberg Heights, Parkville, St Leonards
2026-07-08
Recruiting
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
NCT07630974Malignant Neoplasm
DrugIfinatamab Deruxtecan
Merck Sharp & Dohme LLC
Phase 1/2
134
Parkville
2026-07-06
Recruiting
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213Type 2 Diabetes Mellitus
DrugsElecoglipron·Semaglutide
AstraZeneca
Phase 3
1,200
Botany, East Toowoomba, Fitzroy, Heidelberg Heights, Kingswood, Melbourne, Parkville, Penrith
2026-07-06
Recruiting
A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07558915Relapsed/Refractory Multiple Myeloma
Genentech, Inc.
Phase 1
160
Parkville
2026-06-23
Recruiting
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
NCT07623525Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
Diagonal Therapeutics, Inc.
Phase 1/2
93
Camperdown, Randwick, Herston, East Melbourne, Parkville, West Perth
2026-06-04
Not yet open
A Phase III Randomised Clinical Trial of Ultrasound Groin Monitoring Versus Groin Lymph Node Dissection to De-Escalate the Extent of Surgery in Vulvar Cancer
NCT06476639Vulvar Cancer Stage I, Vulvar Cancer Stage II, Lymph Node Metastasis, Groin Node
Queensland Centre for Gynaecological Cancer
Phase 3
640
Newcastle, Darwin, Auchenflower, Brisbane, Buderim, Adelaide, Heidelberg, Parkville
2026-06-01
Recruiting
TAG TEAM - Trans Adolescent Group Therapy
NCT07151079Minority Stress, Acceptability, Psychological Distress, Anxiety
Murdoch Childrens Research Institute
Not applicable
142
Parkville
2026-05-21
Recruiting
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
NCT06948214Growth Hormone Deficiency (GHD)
DrugLUM-201
Lumos Pharma
Phase 3
150
South Brisbane, Clayton, Parkville
2026-05-20
Recruiting
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
NCT07541287IgA Nephropathy
DrugJADE101
Jade Biosciences, Inc.
Phase 2
30
Concord, Liverpool, Parkville
2026-05-19
Recruiting
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
NCT07573462Pneumococcal Disease
DrugsPG4·20-valent pneumococcal conjugate vaccine
Pfizer
Phase 3
2,400
Westmead, Brisbane, South Brisbane, Clayton, Parkville, Nedlands
2026-05-04
Recruiting
Optimising Breathing Support at Extubation in Very Preterm Infants: A Clinical Study
NCT07251790Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant
Murdoch Childrens Research Institute
Not applicable
134
Melbourne, Parkville, Saint Albans
2026-05-04
By invitation
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
NCT07393373Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2
135
Parkville
2026-04-23
Recruiting
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
NCT07441876Achondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2/3
160
Parkville
2026-04-20
Recruiting
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
NCT07158242Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
100
South Brisbane, Parkville, Nedlands
2026-04-15
By invitation
An Extension of SKY-0515 in Participants With Huntington's Disease
NCT07537075Huntington's Disease (HD)
DrugSKY-0515
Skyhawk Therapeutics, Inc.
Phase 2/3
500
New Lambton Heights, Westmead, Herston, Adelaide, Caulfield South, Parkville, Nedlands
2026-04-10
Recruiting
Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)
NCT07298473Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation (PAF)
Medtronic Cardiac Ablation Solutions
Not applicable
400
Westmead, Adelaide, Parkville
2026-04-08
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
DrugsPumitamig·Ipilimumab
Bristol-Myers Squibb
Phase 1/2
198
Camperdown, Westmead, Birtinya, Parkville
2026-03-16
Recruiting
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
NCT07412470Kidney Transplant Rejection
DrugsRabbit anti-thymocyte globulin·Frexalimab·Mycophenolate Mofetil·Tacrolimus
Sanofi
Phase 2/3
526
Sydney, Adelaide, Clayton, Parkville
2026-03-13
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302Acute Ischemic Stroke
DrugTenecteplase
Boehringer Ingelheim
Phase 3
1,325
Campbelltown, Liverpool, New Lambton Heights, Adelaide, Box Hill, Clayton, Parkville
2026-02-17
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Concord, Kingswood, Kogarah, Herston, Southport, Adelaide, Parkville
2026-02-16
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
300
Adelaide, Brisbane, Heidelberg West, Ipswich, Melbourne, Oaklands Park, Parkville, Perth
2026-02-05
Not yet open
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin
NCT07225465Type 1 Diabetes Mellitus
DrugDapagliflozin
St Vincent's Hospital Melbourne
Phase 2
115
Fitzroy, Heidelberg, Melbourne, Parkville
2026-02
Recruiting
A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)
NCT07359183Food Allergies, Peanut Allergies, Egg Allergy, Milk Allergy
Murdoch Childrens Research Institute
Observational
147
Parkville
2026-01-13
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
150
Adelaide, Box Hill, Brisbane, Melbourne, Parkville, Perth, Randwick, Westmead
2026-01-12
Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
NCT07194070Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Observational
175
Parkville, South Brisbane
2025-12-17
Recruiting
Study of DONQ52 in Active Celiac Disease
NCT07239336Celiac Disease
Chugai Pharmaceutical
Phase 2
92
Campbelltown, North Sydney, Morayfield, Sippy Downs, South Brisbane, Box Hill, Parkville, Midland
2025-12-16
Recruiting
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
NCT07062588Osteogenesis Imperfecta (OI)
Angitia Incorporated Limited
Phase 2
80
Melbourne, Parkville, Saint Leonards, Westmead
2025-12-12
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
Herston, Woolloongabba, Adelaide, Parkville, Nedlands
2025-12-11
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEYยฎ Kids)
NCT07107945Chronic Kidney Disease
DrugDapagliflozin
Boehringer Ingelheim
Phase 3
120
Westmead, South Brisbane, Clayton, Parkville
2025-12-09
Recruiting
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
NCT06816927Newly Diagnosed Glioblastoma
DrugsRelatlimab·Nivolumab
Duke University
Phase 2
92
Parkville
2025-11-28
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531Type 1 Diabetes
SAb Biotherapeutics, Inc.
Phase 2
159
Brisbane, Nedlands, Parkville, St Leonards, Westmead
2025-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 3
900
Kogarah, Westmead, Woolloongabba, Clayton, Parkville, Prahan, Nedlands
2025-11-24
Active, closed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
NCT07246941Huntington's Disease
Hoffmann-La Roche
Phase 1
3
Westmead, Clayton, Parkville
2025-11-19
Recruiting
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
NCT07169279Achondroplasia
QED Therapeutics, a BridgeBio company
Phase 2
77
Parkville
2025-11-19
Recruiting
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
NCT07220811Ig-E Mediated Food Allergy
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Phase 2
100
Darlinghurst, Westmead, South Brisbane, North Adelaide, Clayton, Parkville, Nedlands, Perth
2025-10-22
Recruiting
SOS for Caregiver Wellbeing
NCT07136584Mental Health, Depression and Burden in Caregivers, Anxiety Depression, Stress
Murdoch Childrens Research Institute
Not applicable
100
Parkville
2025-10-22
Recruiting
A Study of JNT-517 in Participants With Phenylketonuria (PKU)
NCT06971731Phenylketonuria
DrugJNT-517
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
120
Adelaide, Parkville, South Brisbane
2025-10-20
Recruiting
Wearable Technology and Machine Learning for Early Detection and Risk Assessment of Unacceptable Toxicities in a Paediatric Oncology Cohort
NCT07030998Cancer, Infection, Digital Health, Wearable Devices
Murdoch Childrens Research Institute
Observational
150
Parkville
2025-10-15
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Clayton, Concord, Fitzroy, Murdoch, New Lambton Heights, Parkville, South Brisbane
2025-10-01
Recruiting
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT07157787Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.
Phase 2
30
Gosford, Parkville, Southport
2025-09-19
Recruiting
Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
NCT07055542Allergic Asthma, Thunderstorm Asthma, Seasonal Allergic Rhinitis, Grass Pollen Allergy
University of Melbourne
Not applicable
530
Albury, Box Hill, Clayton, Heidelberg, Melbourne, Parkville
2025-08-27
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321Invasive Mold Infections
DrugFosmanogepix
Basilea Pharmaceutica
Phase 3
234
Clayton, Melbourne, Parkville, Westmead, Woolloongabba
2025-08-26
Recruiting
An International Observational Study of Adults With Acute Infection
NCT07069400Infectious Disease
University of Minnesota
Observational
1,500
Camperdown, Sydney, Westmead, Brisbane, Clayton, Heidelberg, Melbourne, Parkville
2025-08-25
Recruiting
Study of BHV-1300 in Graves' Disease
NCT06980649Graves Disease
DrugBHV-1300
Biohaven Therapeutics Ltd.
Phase 1
15
Fitzroy, Herston, Kotara, Melbourne, Oaklands Park, Parkville, St Leonards, Torquay
2025-08-21
Recruiting
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT07196501Major Depressive Disorder
DrugNBI-1065845
Neurocrine Biosciences
Phase 3
550
Carlton, Melbourne, Parkville
2025-08-18
Recruiting
A Long-Term Study of JNT-517 in Participants With Phenylketonuria
NCT06628128Phenylketonuria (PKU)
DrugJNT-517
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
240
South Brisbane, Adelaide, Parkville
2025-08-11
Active, closed
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199Diabetes Mellitus, Type 1
DrugsInsulin glargine·Insulin aspart·Insulin icodec
Novo Nordisk A/S
Phase 3
877
Macquarie Park, Wollongong, Townsville, Oaklands Park, Fitzroy, Heidelberg Heights, Parkville
2025-08-11
Recruiting
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2
60
South Brisbane, Parkville
2025-07-30
Recruiting
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
NCT07082725Niemann-Pick Type C Disease
DrugNizubaglustat
Azafaros B.V.
Phase 3
72
North Adelaide, Parkville
2025-06-30
Recruiting
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07054515Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
DrugNizubaglustat
Azafaros B.V.
Phase 3
147
North Adelaide, Parkville
2025-06-30
Active, closed
Safety Study of Viaskinยฎ Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
NCT07003919Allergy, Peanut Allergy
DBV Technologies
Phase 3
480
Westmead, South Brisbane, Parkville, Richmond, Nedlands
2025-06-24
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281Relapsing Multiple Sclerosis
DrugsRemibrutinib·Ocrelizumab
Novartis Pharmaceuticals
Phase 3
400
Melbourne, Parkville, Liverpool, St Leonards
2025-06-23
By invitation
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
NCT07073014Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 3
140
Parkville
2025-06-20
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT07018323Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
210
Sydney, Warrawong, Brisbane, Douglas, Southport, Box Hill, Geelong, Parkville
2025-06-19
Recruiting
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
NCT06944522Parkinsons Disease (PD)
BlueRock Therapeutics
Phase 3
102
Randwick, Southport, Woolloongabba, Clayton, Melbourne, Parkville
2025-06-17
Recruiting
A Phase 2 Study of Mutant-selective PI3Kฮฑ Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
NCT06789913PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation
DrugRLY-2608
Relay Therapeutics, Inc.
Phase 2
277
Randwick, South Brisbane, Clayton, Parkville
2025-06-13
Recruiting
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
NCT06953583Friedreich Ataxia
DrugsSkyclarys·Omaveloxolone
Biogen
Phase 3
255
Randwick, Parkville
2025-06-09
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT06782490Multiple Sclerosis Spasticity
DrugIrafamdastat
Celgene
Phase 2
200
Newcastle, Sydney, Kent Town, Box Hill, Heidelberg, Parkville, Nedlands
2025-06-05
Active, closed
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
NCT07027527Atopic Dermatitis
DrugsAPG777·Dupilumab
Apogee Therapeutics, Inc.
Phase 1
86
Darlinghurst, Kogarah, Westmead, Woolloongabba, Carlton, East Melbourne, Mitcham, Parkville
2025-06-04
Active, closed
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
NCT06735534Persistent Atrial Fibrillation
Boston Scientific Corporation
Not applicable
376
New Lambton Heights, Westmead, Brisbane, Clayton, Parkville, Melbourne
2025-06-03
Recruiting
Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
NCT06850727Ulcerative Colitis (UC), UC - Ulcerative Colitis
DrugVedolizumab
Odyssey Therapeutics
Phase 2
57
Birtinya, Box Hill, Maroochydore, Melbourne, Murdoch, Parkville
2025-06-02
Recruiting
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157B Acute Lymphoblastic Leukemia
DrugsCalaspargase Pegol·Dasatinib·Imatinib·Blinatumomab
National Cancer Institute (NCI)
Phase 2
222
Hunter Regional Mail Centre, South Brisbane, Parkville, Perth
2025-05-30
Active, closed
Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease
NCT06873334Huntington Disease, Huntingtons Disease
DrugSKY-0515
Skyhawk Therapeutics, Inc.
Phase 2/3
120
New Lambton Heights, Westmead, Herston, Adelaide, Launceston, Caulfield South, Parkville, Nedlands
2025-05-27
Recruiting
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
NCT06941272Malignant Neoplasm
DrugPatritumab deruxtecan
Merck Sharp & Dohme LLC
Phase 1/2
50
Sydney, Brisbane, Parkville
2025-05-26
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
425
Macquarie Park, Wahroonga, Mackay, Footscray, Parkville
2025-05-12
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285Myelodysplastic Syndromes
DrugElritercept
Takeda
Phase 3
225
Garran, Sydney, Douglas, Adelaide, Box Hill, Fitzroy, Melbourne, Parkville
2025-05-06
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
NCT06884618Neoplasms
Hoffmann-La Roche
Phase 1
405
Darlinghurst, Parkville
2025-04-30
By invitation
An Interventional Study of Infigratinib in Children With Hypochondroplasia
NCT06873035Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2/3
24
Parkville
2025-04-22
Recruiting
Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels
NCT05766839Hyperkalemia
DrugPatiromer
Vifor Pharma, Inc.
Phase 2
36
Clayton, Parkville, Westmead
2025-04-06
Active, closed
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
NCT06910358Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
DrugBitopertin
Disc Medicine, Inc
Phase 3
183
Camperdown, Parkville
2025-04-04
Active, closed
Hybrid Type 2 Implementation-Effectiveness Trial of a Third Wave Virtual Reality Treatment for Youth Depression/Anxiety
NCT06894836Depression Anxiety Disorder
Orygen
Phase 2
75
Parkville
2025-04-01
Recruiting
Diagnostic Performance Study of the EMVision Emuโ„ข Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
NCT06999122Stroke, Hemorrhagic Stroke
EMVision Medical Devices Ltd
Observational
300
Liverpool, Parkville
2025-03-26
Recruiting
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662Chronic Inflammatory Demyelinating Polyneuropathy
Immunovant Sciences GmbH
Phase 2
162
Macquarie Park, Parkville, Woolloongabba
2025-03-18
Recruiting
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
NCT06842355Achondroplasia
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
92
Westmead, Parkville
2025-03-04
Active, closed
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobodyยฎ Molecule
NCT06812988Type 1 Diabetes Mellitus
DrugBrivekimig
Sanofi
Phase 2
84
Saint Leonards, Brisbane, Parkville
2025-02-28
Recruiting
A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia and Their Children up to 24 Months
NCT07282171sFlt1 Mediated Preterm Preeclampsia, Preeclampsia, Preterm Preeclampsia
Comanche Biopharma
Phase 1
60
Parkville, Melbourne
2025-02-26
Recruiting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease
NCT06732180Parkinson Disease
Gain Therapeutics, Inc.
Phase 1
20
Darlinghurst, Kogarah, Westmead, Woolloongabba, Adelaide, Melbourne, Parkville
2025-02-21
By invitation
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226Developmental and Epileptic Encephalopathy
DrugLP352
Longboard Pharmaceuticals
Phase 3
324
Randwick, Westmead, Brisbane, Heidelberg, Parkville
2025-02-12
By invitation
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06679881Hereditary Angioedema (HAE)
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 3
170
Box Hill, Parkville, Perth, Sydney
2025-02-01
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
588
Phillip, Sydney, Westmead, Melbourne, Parkville
2025-01-31
Recruiting
Prehabilitation for Patients Undergoing Lung Cancer Surgery
NCT06716437Lung Cancer (NSCLC)
University of Melbourne
Not applicable
25
Parkville
2025-01-24
Recruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
NCT06613360SLE, SLE (Systemic Lupus)
DrugCLN-978
Cullinan Therapeutics Inc.
Phase 1
24
Parkville, Victoria Park
2025-01-21
Active, closed
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
NCT06634420Hereditary Angioedema
Intellia Therapeutics
Phase 3
80
Campbelltown, Melbourne, Parkville
2025-01-15
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
DrugsPF-07220060·Ribociclib·Abemaciclib·Palbociclib
Pfizer
Phase 3
1,035
Douglas, Woolloongabba, Capel Sound, Melbourne, Parkville
2025-01-06
Recruiting
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
NCT06524830Treatment Resistant Depression
atai Therapeutics, Inc.
Phase 2
142
Camperdown, Carlton, Melbourne, Northcote, Parkville
2024-12-30
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
DrugsBrivekimig·Frexalimab·Rilzabrutinib
Sanofi
Phase 2
84
Garran, Parkville
2024-12-19
Active, closed
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06736041Pneumococcal Immunization
DrugsM-M-R II vaccine·Prevnar 20 vaccine·RotaTeq·Vaxelis vaccine
Sanofi Pasteur, a Sanofi Company
Phase 3
1,714
Westmead, Brisbane, Southport, Parkville, Perth
2024-12-18
Active, closed
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
NCT06742190Multifocal Motor Neuropathy (MMN), MMN
DrugsEmpasiprubart·Immunoglobulin·IVIG
argenx
Phase 3
154
Parkville, Southport, Sydney, Woolloongabba
2024-12-18
Not yet open
Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure
NCT06681636HPV Infection, Cervical Cancer, Anogenital Cancer, Anogenital Warts
DrugHPV nonavalent vaccine
National Institute of Hygiene and Epidemiology, Vietnam
Phase 2
300
Parkville
2024-12-14
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
350
Macquarie Park, Mackay, Footscray, Parkville
2024-12-11
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
DrugsCaspofungin·Fosmanogepix·Fluconazole
Basilea Pharmaceutica
Phase 3
450
Sydney, Woolloongabba, Melbourne, Parkville, Clayton
2024-12-11
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
NCT06637631Crohn's Disease
DrugSAR441566
Sanofi
Phase 2
260
Sydney, South Brisbane, Parkville
2024-12-10
Recruiting
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
NCT06667908Carcinoma, Non-Small-Cell Lung
DrugsJNJ-90301900·Durvalumab
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
Herston, Nedlands, North Ryde, Parkville
2024-12-06
Rows per page Showing 1–100 of 317
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-australia/city/parkville

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,331 studies in total at the last sync on 26 Sep 2026, 19:46 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 317 of those studies with a site in Parkville.

How many clinical trials are recruiting in Parkville?

158 of the 317 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:46 UTC sync. A further 6 have not yet opened recruitment, 138 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Parkville), 317 studies
PhaseStudiesRecruitingShare
Phase 31335342%
Phase 2744323.3%
Observational322210.1%
Not applicable24147.6%
Phase 1/222136.9%
Phase 11574.7%
Phase 2/31233.8%
Phase 4531.6%

Most active sponsors

Lead sponsors with the most studies (Parkville)
Lead sponsorStudiesRecruiting
Murdoch Childrens Research Institute1611
Children's Oncology Group158
Hoffmann-La Roche156
BioMarin Pharmaceutical114
Novartis Pharmaceuticals102
National Cancer Institute (NCI)94
Janssen Research & Development, LLC82
Pfizer83
AstraZeneca73
Sanofi72
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.